Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient.
J Pharm Sci
; 102(6): 1859-1868, 2013 Jun.
Article
em En
| MEDLINE
| ID: mdl-23568749
ABSTRACT
Tenofovir is a nucleoside reverse-transcriptase inhibitor that is currently being investigated as a potential HIV microbicide candidate, with a recent phase IIb study of a 1% (w/w) tenofovir gel reducing HIV acquisition by 39% in sexually active women. However, not only does a HIV microbicidal product need to be safe and effective, it also needs to be cheap and easy to manufacture. In this study, we report the development of a tenofovir-loaded tablet, manufactured using a single sustained-release polymer, which has an acceptable hardness, friability and tenofovir release rate. Furthermore, by varying both the type and molecular weight of the sustained-release polymer, as well as the particle size of both tenofovir and the sustained-release polymer, we can vary the release rate of tenofovir from the tablets.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polímeros
/
Adenina
/
Fármacos Anti-HIV
/
Preparações de Ação Retardada
/
Excipientes
/
Organofosfonatos
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article